Thermo Fisher (TMO) Stock Forecast & Price Target

Compare

5,050 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TMO Analyst Ratings

Strong Buy

20 Buy

1 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Thermo

Fisher

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TMO Stock 12 Month Forecast

Average Price Target

$640.30

▲(12.76% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Thermo Fisher in the last 3 months. The average price target is $640.30 with a high forecast of $750.00 and a low forecast of $570.00. The average price target represents a 12.76% change from the last price of $567.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"394":"$394","751":"$751","483.25":"$483.3","572.5":"$572.5","661.75":"$661.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":750,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$750.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":640.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$640.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":570,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$570.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[394,483.25,572.5,661.75,751],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.71,597.4246153846154,610.1392307692308,622.8538461538462,635.5684615384615,648.2830769230769,660.9976923076923,673.7123076923077,686.4269230769231,699.1415384615385,711.8561538461538,724.5707692307692,737.2853846153846,{"y":750,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.71,588.9861538461539,593.2623076923077,597.5384615384615,601.8146153846154,606.0907692307692,610.3669230769231,614.6430769230769,618.9192307692308,623.1953846153846,627.4715384615384,631.7476923076923,636.0238461538461,{"y":640.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.71,583.5784615384616,582.4469230769231,581.3153846153847,580.1838461538462,579.0523076923077,577.9207692307692,576.7892307692308,575.6576923076923,574.5261538461539,573.3946153846153,572.2630769230769,571.1315384615384,{"y":570,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":527.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":518.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":595.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":527.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":481.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":395.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":420.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":530.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":566.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$750.00

Average Price Target$640.30

Lowest Price Target$570.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brandon Couillard

Wells Fargo

$635→$675

Buy

18.87%

Upside

Reiterated

12/15/25

Analysts' Top Healthcare Picks: Novan (NOVN), Thermo Fisher (TMO)

Michael Ryskin

Bank of America Securities

$650→$700

Buy

23.28%

Upside

Reiterated

12/15/25

Bank of America Securities Sticks to Their Buy Rating for Thermo Fisher (TMO)

Casey Woodring

J.P. Morgan

$675

Buy

18.87%

Upside

Reiterated

12/15/25

J.P. Morgan Remains a Buy on Thermo Fisher (TMO)

Patrick B Donnelly

Citi

$580→$660

Buy

16.23%

Upside

Upgraded

12/11/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Evie Koslosky

Goldman Sachs

$685

Buy

20.63%

Upside

Initiated

12/09/25

Thermo Fisher initiated with a Buy at Goldman SachsThermo Fisher initiated with a Buy at Goldman Sachs

Paul Knight

KeyBanc

$750

Buy

32.08%

Upside

Upgraded

12/08/25

Thermo Fisher upgraded to Overweight from Sector Weight at KeyBancThermo Fisher upgraded to Overweight from Sector Weight at KeyBanc

Kallum Titchmarsh

Morgan Stanley

$656→$670

Buy

17.99%

Upside

Initiated

12/01/25

Thermo Fisher assumed with an Overweight at Morgan StanleyThermo Fisher assumed with an Overweight at Morgan Stanley

Sidharth Sahoo

HSBC

$670

Buy

17.99%

Upside

Upgraded

12/01/25

Thermo Fisher upgraded to Buy from Hold at HSBCThermo Fisher upgraded to Buy from Hold at HSBC

Daniel Arias

Stifel Nicolaus

$583

Buy

2.67%

Upside

Reiterated

11/03/25

Stifel Nicolaus Sticks to Its Buy Rating for Thermo Fisher (TMO)

Luke Sergott

Barclays

$625

Buy

10.07%

Upside

Reiterated

10/30/25

Analysts Conflicted on These Healthcare Names: Bausch Health Companies (NYSE: BHC), Thermo Fisher (NYSE: TMO) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Matt Larew

William Blair

Buy

―

Reiterated

10/29/25

Thermo Fisher's Strategic Acquisition of Clario: A Buy Rating with Promising Financial and Growth Prospects

David Toung

Argus Research

$580→$610

Buy

7.43%

Upside

Reiterated

10/28/25

Argus Research Keeps Their Buy Rating on Thermo Fisher (TMO)

Jill Wu

CMB International Securities

$553→$654

Buy

15.18%

Upside

Reiterated

10/24/25

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN) and Thermo Fisher (NYSE: TMO)

Daniel Brennan

TD Cowen

$612→$654

Buy

15.18%

Upside

Reiterated

10/23/25

Thermo Fisher's Strong Q3 Performance and Positive Outlook Drive Buy Rating

Dan Leonard

UBS

$500→$590

Hold

3.90%

Upside

Reiterated

10/23/25

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Intuitive Surgical (NASDAQ: ISRG)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brandon Couillard

Wells Fargo

$635→$675

Buy

18.87%

Upside

Reiterated

12/15/25

Analysts' Top Healthcare Picks: Novan (NOVN), Thermo Fisher (TMO)

Michael Ryskin

Bank of America Securities

$650→$700

Buy

23.28%

Upside

Reiterated

12/15/25

Bank of America Securities Sticks to Their Buy Rating for Thermo Fisher (TMO)

Casey Woodring

J.P. Morgan

$675

Buy

18.87%

Upside

Reiterated

12/15/25

J.P. Morgan Remains a Buy on Thermo Fisher (TMO)

Patrick B Donnelly

Citi

$580→$660

Buy

16.23%

Upside

Upgraded

12/11/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Evie Koslosky

Goldman Sachs

$685

Buy

20.63%

Upside

Initiated

12/09/25

Thermo Fisher initiated with a Buy at Goldman SachsThermo Fisher initiated with a Buy at Goldman Sachs

Paul Knight

KeyBanc

$750

Buy

32.08%

Upside

Upgraded

12/08/25

Thermo Fisher upgraded to Overweight from Sector Weight at KeyBancThermo Fisher upgraded to Overweight from Sector Weight at KeyBanc

Kallum Titchmarsh

Morgan Stanley

$656→$670

Buy

17.99%

Upside

Initiated

12/01/25

Thermo Fisher assumed with an Overweight at Morgan StanleyThermo Fisher assumed with an Overweight at Morgan Stanley

Sidharth Sahoo

HSBC

$670

Buy

17.99%

Upside

Upgraded

12/01/25

Thermo Fisher upgraded to Buy from Hold at HSBCThermo Fisher upgraded to Buy from Hold at HSBC

Daniel Arias

Stifel Nicolaus

$583

Buy

2.67%

Upside

Reiterated

11/03/25

Stifel Nicolaus Sticks to Its Buy Rating for Thermo Fisher (TMO)

Luke Sergott

Barclays

$625

Buy

10.07%

Upside

Reiterated

10/30/25

Analysts Conflicted on These Healthcare Names: Bausch Health Companies (NYSE: BHC), Thermo Fisher (NYSE: TMO) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Matt Larew

William Blair

Buy

―

Reiterated

10/29/25

Thermo Fisher's Strategic Acquisition of Clario: A Buy Rating with Promising Financial and Growth Prospects

David Toung

Argus Research

$580→$610

Buy

7.43%

Upside

Reiterated

10/28/25

Argus Research Keeps Their Buy Rating on Thermo Fisher (TMO)

Jill Wu

CMB International Securities

$553→$654

Buy

15.18%

Upside

Reiterated

10/24/25

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN) and Thermo Fisher (NYSE: TMO)

Daniel Brennan

TD Cowen

$612→$654

Buy

15.18%

Upside

Reiterated

10/23/25

Thermo Fisher's Strong Q3 Performance and Positive Outlook Drive Buy Rating

Dan Leonard

UBS

$500→$590

Hold

3.90%

Upside

Reiterated

10/23/25

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO) and Intuitive Surgical (NASDAQ: ISRG)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Thermo Fisher

1 Month

xxx

Success Rate

12/19 ratings generated profit

Average Return

+1.09%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +1.09% per trade.

3 Months

xxx

Success Rate

30/43 ratings generated profit

Average Return

+4.35%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.77% of your transactions generating a profit, with an average return of +4.35% per trade.

1 Year

Sung Ji NamScotiabank

Success Rate

16/19 ratings generated profit

Average Return

+16.59%

reiterated a buy rating 5 months ago

Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +16.59% per trade.

2 Years

xxx

Success Rate

16/19 ratings generated profit

Average Return

+32.81%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.21% of your transactions generating a profit, with an average return of +32.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TMO Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TMO has received 36 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TMO average Analyst price target in the past 3 months is 640.30.

Each month's total comprises the sum of three months' worth of ratings.

TMO Financial Forecast

TMO Earnings Forecast

Next quarter’s earnings estimate for TMO is $6.45 with a range of $6.39 to $6.51. The previous quarter’s EPS was $5.79. TMO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TMO has Performed in-line its overall industry.

TMO Sales Forecast

Next quarter’s sales forecast for TMO is $11.95B with a range of $11.82B to $12.01B. The previous quarter’s sales results were $11.12B. TMO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TMO has Performed in-line its overall industry.

TMO Stock Forecast FAQ

What is TMO’s average 12-month price target, according to analysts?

Based on analyst ratings, Thermo Fisher Scientific’s 12-month average price target is 640.30.

What is TMO’s upside potential, based on the analysts’ average price target?

Thermo Fisher Scientific has 12.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TMO a Buy, Sell or Hold?

Thermo Fisher Scientific has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.

What is Thermo Fisher Scientific’s price target?

The average price target for Thermo Fisher Scientific is 640.30. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $750.00 ,the lowest forecast is $570.00. The average price target represents 12.76% Increase from the current price of $567.83.

What do analysts say about Thermo Fisher Scientific?

Thermo Fisher Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of TMO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Thermo Fisher (TMO) Stock Forecast & Price Target

TMO Analyst Ratings

TMO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Thermo Fisher

TMO Analyst Recommendation Trends

TMO Financial Forecast

TMO Earnings Forecast

TMO Sales Forecast

TMO Stock Forecast FAQ

Detailed List of Analyst Forecasts